A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

CAR T-cell therapy on the National Health Service offers adults with fast-moving B-cell leukemia years of life, fewer side ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

China: CAR T-cell therapy, already in use for certain B-cell–driven autoimmune diseases such as lupus, has now demonstrated ...

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...